Shares

3 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2021

Nov 10, 2021

SELL
$1.89 - $8.53 $801 - $3,616
-424 Closed
0 $0
Q2 2021

Aug 11, 2021

SELL
$2.46 - $3.14 $54 - $69
-22 Reduced 4.93%
424 $1,000
Q4 2020

Feb 10, 2021

BUY
$3.56 - $4.86 $1,587 - $2,167
446 New
446 $2,000

Others Institutions Holding CRVS

About Corvus Pharmaceuticals, Inc.


  • Ticker CRVS
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 46,553,500
  • Market Cap $401M
  • Description
  • Corvus Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, focuses on the development and commercialization of immuno-oncology therapies. Its lead product candidate is Mupadolimab (CPI-006), an anti-CD73 monoclonal antibody, which is in Phase Ib/II clinical trial for non-small cell lung cancer and head and neck cancers. The compan...
More about CRVS
Track This Portfolio

Track Panagora Asset Management Inc Portfolio

Follow Panagora Asset Management Inc and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Panagora Asset Management Inc, based on Form 13F filings with the SEC.

News

Stay updated on Panagora Asset Management Inc with notifications on news.